We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Assay Stratifies Esophageal Cancer Patients for Treatment

By LabMedica International staff writers
Posted on 22 May 2019
The incidence of esophageal adenocarcinoma (OAC) in the Western world has risen six-fold in the last 40 years with the highest incidence occurring in the UK and there were about 9,200 cases of the disease reported in the UK in 2015. More...
It accounts for 3% of cancer cases in the UK each year.

Most esophageal cancer patients undergo conventional treatment in which chemotherapy is used to shrink the tumor, followed by surgical removal. However, some patients show no response to chemotherapy at all, making it treatment by chemotherapy unnecessary. Imaging and molecular features of OAC have been studied in an attempt to identify predictive biomarkers to neoadjuvant therapy.

A large team of scientist working with the Queen's University Belfast (Belfast, UK) performed transcriptional profiling of 273 formalin-fixed paraffin-embedded prechemotherapy endoscopic OAC biopsies. All patients were treated with platinum-based neoadjuvant chemotherapy and resection between 2003 and 2014 at four centers. CD8 and programmed death ligand 1 (PD-L1) immunohistochemical staining was assessed in matched resection specimens from 126 cases.

Total RNA was extracted using the Recoverall Total Nucleic Acid Isolation Kit for FFPE and amplified using the NuGen Ovation FFPE Amplification System v3. The amplified product was hybridized to the Almac Diagnostics Xcel array, a cDNA microarray-based technology optimized for archival FFPE tissue and analyzed using the Affymetrix Genechip 7G scanner. The assay gives a DNA damage immune response (DDIR) signature.

The investigators reported that of the 273 samples interrogated, 66, or 24% were DDIR positive. The remainder were DDIR negative. Being DDIR positive was correlated with a higher pathological response rate, as well as the increased presence of CD8+ lymphocytes and PD-L1 expression, both of which signal immune response. Based on these findings, the authors determined the DDIR assay to be "strongly predictive" of benefit from DNA-damaging neoadjuvant chemotherapy followed by surgical resection.

The authors concluded that they have developed an array-based classifier using pretreatment FFPE biopsies to predict benefit from, and response to, neoadjuvant therapy in resectable OAC. The assay is readily applicable to routine pathological samples with potential for rapid translation into clinical use. The study was published originally on March 9, 2019, in the journal GUT.

Related Links:
Queen's University Belfast


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.